nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulfadiazine—CYP2E1—Mitoxantrone—lymphatic system cancer	0.216	0.32	CbGbCtD
Sulfadiazine—CYP2C9—Teniposide—lymphatic system cancer	0.161	0.238	CbGbCtD
Sulfadiazine—CYP3A4—Cytarabine—lymphatic system cancer	0.0948	0.141	CbGbCtD
Sulfadiazine—CYP3A4—Teniposide—lymphatic system cancer	0.0934	0.138	CbGbCtD
Sulfadiazine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0653	0.0968	CbGbCtD
Sulfadiazine—CYP3A4—Vincristine—lymphatic system cancer	0.045	0.0666	CbGbCtD
Sulfadiazine—Crystalluria—Fludarabine—lymphatic system cancer	0.0175	0.0539	CcSEcCtD
Sulfadiazine—Periorbital oedema—Bleomycin—lymphatic system cancer	0.00848	0.0261	CcSEcCtD
Sulfadiazine—Skin necrosis—Carmustine—lymphatic system cancer	0.00837	0.0257	CcSEcCtD
Sulfadiazine—Oliguria—Mechlorethamine—lymphatic system cancer	0.00765	0.0235	CcSEcCtD
Sulfadiazine—Necrolysis epidermal—Methotrexate—lymphatic system cancer	0.00597	0.0184	CcSEcCtD
Sulfadiazine—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.00567	0.0174	CcSEcCtD
Sulfadiazine—Sepsis—Teniposide—lymphatic system cancer	0.00451	0.0139	CcSEcCtD
Sulfadiazine—Burning sensation—Carmustine—lymphatic system cancer	0.00421	0.0129	CcSEcCtD
Sulfadiazine—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.00418	0.0129	CcSEcCtD
Sulfadiazine—Reaction gastrointestinal—Methotrexate—lymphatic system cancer	0.00406	0.0125	CcSEcCtD
Sulfadiazine—Depression—Mechlorethamine—lymphatic system cancer	0.00393	0.0121	CcSEcCtD
Sulfadiazine—Skin necrosis—Methotrexate—lymphatic system cancer	0.00388	0.0119	CcSEcCtD
Sulfadiazine—Anuria—Methotrexate—lymphatic system cancer	0.00388	0.0119	CcSEcCtD
Sulfadiazine—Neuritis—Vincristine—lymphatic system cancer	0.00374	0.0115	CcSEcCtD
Sulfadiazine—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.00368	0.0113	CcSEcCtD
Sulfadiazine—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.00335	0.0103	CcSEcCtD
Sulfadiazine—Tinnitus—Mechlorethamine—lymphatic system cancer	0.0033	0.0102	CcSEcCtD
Sulfadiazine—Skin exfoliation—Bleomycin—lymphatic system cancer	0.0032	0.00984	CcSEcCtD
Sulfadiazine—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00299	0.00919	CcSEcCtD
Sulfadiazine—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.00285	0.00877	CcSEcCtD
Sulfadiazine—Stomatitis—Teniposide—lymphatic system cancer	0.00284	0.00872	CcSEcCtD
Sulfadiazine—Skin exfoliation—Carmustine—lymphatic system cancer	0.00279	0.00859	CcSEcCtD
Sulfadiazine—Vertigo—Mechlorethamine—lymphatic system cancer	0.00277	0.00852	CcSEcCtD
Sulfadiazine—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00276	0.00849	CcSEcCtD
Sulfadiazine—Sepsis—Carmustine—lymphatic system cancer	0.00254	0.00781	CcSEcCtD
Sulfadiazine—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00253	0.0078	CcSEcCtD
Sulfadiazine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00252	0.00774	CcSEcCtD
Sulfadiazine—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00251	0.00771	CcSEcCtD
Sulfadiazine—Stomatitis—Fludarabine—lymphatic system cancer	0.00249	0.00766	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00246	0.00758	CcSEcCtD
Sulfadiazine—Anorexia—Mechlorethamine—lymphatic system cancer	0.0024	0.00738	CcSEcCtD
Sulfadiazine—Sepsis—Mitoxantrone—lymphatic system cancer	0.00236	0.00726	CcSEcCtD
Sulfadiazine—Chills—Teniposide—lymphatic system cancer	0.00234	0.00721	CcSEcCtD
Sulfadiazine—Polyuria—Vincristine—lymphatic system cancer	0.00231	0.0071	CcSEcCtD
Sulfadiazine—Eruption—Methotrexate—lymphatic system cancer	0.0022	0.00677	CcSEcCtD
Sulfadiazine—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00219	0.00673	CcSEcCtD
Sulfadiazine—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00217	0.00667	CcSEcCtD
Sulfadiazine—Chills—Fludarabine—lymphatic system cancer	0.00206	0.00633	CcSEcCtD
Sulfadiazine—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00204	0.00627	CcSEcCtD
Sulfadiazine—Leukopenia—Teniposide—lymphatic system cancer	0.00203	0.00626	CcSEcCtD
Sulfadiazine—Ataxia—Carmustine—lymphatic system cancer	0.002	0.00614	CcSEcCtD
Sulfadiazine—Burning sensation—Methotrexate—lymphatic system cancer	0.00195	0.006	CcSEcCtD
Sulfadiazine—Ataxia—Vincristine—lymphatic system cancer	0.00191	0.00586	CcSEcCtD
Sulfadiazine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00185	0.0057	CcSEcCtD
Sulfadiazine—Stomatitis—Bleomycin—lymphatic system cancer	0.00183	0.00562	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00182	0.00559	CcSEcCtD
Sulfadiazine—Leukopenia—Fludarabine—lymphatic system cancer	0.00179	0.0055	CcSEcCtD
Sulfadiazine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00178	0.00548	CcSEcCtD
Sulfadiazine—Anorexia—Teniposide—lymphatic system cancer	0.00177	0.00544	CcSEcCtD
Sulfadiazine—Convulsion—Fludarabine—lymphatic system cancer	0.00173	0.00532	CcSEcCtD
Sulfadiazine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00172	0.0053	CcSEcCtD
Sulfadiazine—Arthralgia—Fludarabine—lymphatic system cancer	0.0017	0.00523	CcSEcCtD
Sulfadiazine—Depression—Carmustine—lymphatic system cancer	0.00163	0.00502	CcSEcCtD
Sulfadiazine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00163	0.00501	CcSEcCtD
Sulfadiazine—Decreased appetite—Teniposide—lymphatic system cancer	0.00161	0.00496	CcSEcCtD
Sulfadiazine—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.0016	0.00493	CcSEcCtD
Sulfadiazine—Vomiting—Mechlorethamine—lymphatic system cancer	0.0016	0.00492	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.0016	0.00491	CcSEcCtD
Sulfadiazine—Stomatitis—Carmustine—lymphatic system cancer	0.00159	0.00491	CcSEcCtD
Sulfadiazine—Rash—Mechlorethamine—lymphatic system cancer	0.00159	0.00488	CcSEcCtD
Sulfadiazine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00159	0.00488	CcSEcCtD
Sulfadiazine—Depression—Vincristine—lymphatic system cancer	0.00156	0.00479	CcSEcCtD
Sulfadiazine—Anorexia—Fludarabine—lymphatic system cancer	0.00155	0.00478	CcSEcCtD
Sulfadiazine—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00153	0.00471	CcSEcCtD
Sulfadiazine—Stomatitis—Vincristine—lymphatic system cancer	0.00152	0.00468	CcSEcCtD
Sulfadiazine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00152	0.00467	CcSEcCtD
Sulfadiazine—Chills—Bleomycin—lymphatic system cancer	0.00151	0.00464	CcSEcCtD
Sulfadiazine—Skin discolouration—Methotrexate—lymphatic system cancer	0.0015	0.00461	CcSEcCtD
Sulfadiazine—Nausea—Mechlorethamine—lymphatic system cancer	0.00149	0.0046	CcSEcCtD
Sulfadiazine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00149	0.00457	CcSEcCtD
Sulfadiazine—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00148	0.00456	CcSEcCtD
Sulfadiazine—Urticaria—Teniposide—lymphatic system cancer	0.00147	0.00453	CcSEcCtD
Sulfadiazine—Oliguria—Methotrexate—lymphatic system cancer	0.00147	0.00452	CcSEcCtD
Sulfadiazine—Body temperature increased—Teniposide—lymphatic system cancer	0.00147	0.00451	CcSEcCtD
Sulfadiazine—Abdominal pain—Teniposide—lymphatic system cancer	0.00147	0.00451	CcSEcCtD
Sulfadiazine—Hallucination—Carmustine—lymphatic system cancer	0.00146	0.00449	CcSEcCtD
Sulfadiazine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00142	0.00437	CcSEcCtD
Sulfadiazine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00142	0.00436	CcSEcCtD
Sulfadiazine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00141	0.00433	CcSEcCtD
Sulfadiazine—Hallucination—Vincristine—lymphatic system cancer	0.0014	0.00429	CcSEcCtD
Sulfadiazine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00137	0.0042	CcSEcCtD
Sulfadiazine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00137	0.0042	CcSEcCtD
Sulfadiazine—Pruritus—Teniposide—lymphatic system cancer	0.00131	0.00404	CcSEcCtD
Sulfadiazine—Leukopenia—Bleomycin—lymphatic system cancer	0.00131	0.00403	CcSEcCtD
Sulfadiazine—Skin exfoliation—Methotrexate—lymphatic system cancer	0.00129	0.00398	CcSEcCtD
Sulfadiazine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00129	0.00396	CcSEcCtD
Sulfadiazine—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00127	0.00391	CcSEcCtD
Sulfadiazine—Diarrhoea—Teniposide—lymphatic system cancer	0.00127	0.0039	CcSEcCtD
Sulfadiazine—Chills—Mitoxantrone—lymphatic system cancer	0.00123	0.00377	CcSEcCtD
Sulfadiazine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.0012	0.00369	CcSEcCtD
Sulfadiazine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.0012	0.00368	CcSEcCtD
Sulfadiazine—Vomiting—Teniposide—lymphatic system cancer	0.00118	0.00363	CcSEcCtD
Sulfadiazine—Sepsis—Methotrexate—lymphatic system cancer	0.00118	0.00362	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00117	0.0036	CcSEcCtD
Sulfadiazine—Rash—Teniposide—lymphatic system cancer	0.00117	0.0036	CcSEcCtD
Sulfadiazine—Dermatitis—Teniposide—lymphatic system cancer	0.00117	0.00359	CcSEcCtD
Sulfadiazine—Headache—Teniposide—lymphatic system cancer	0.00116	0.00357	CcSEcCtD
Sulfadiazine—Pruritus—Fludarabine—lymphatic system cancer	0.00115	0.00355	CcSEcCtD
Sulfadiazine—Leukopenia—Carmustine—lymphatic system cancer	0.00114	0.00352	CcSEcCtD
Sulfadiazine—Anorexia—Bleomycin—lymphatic system cancer	0.00114	0.0035	CcSEcCtD
Sulfadiazine—Polyuria—Methotrexate—lymphatic system cancer	0.00112	0.00344	CcSEcCtD
Sulfadiazine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00112	0.00343	CcSEcCtD
Sulfadiazine—Convulsion—Carmustine—lymphatic system cancer	0.00111	0.00341	CcSEcCtD
Sulfadiazine—Nausea—Teniposide—lymphatic system cancer	0.0011	0.00339	CcSEcCtD
Sulfadiazine—Vertigo—Vincristine—lymphatic system cancer	0.0011	0.00337	CcSEcCtD
Sulfadiazine—Leukopenia—Vincristine—lymphatic system cancer	0.00109	0.00336	CcSEcCtD
Sulfadiazine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00109	0.00335	CcSEcCtD
Sulfadiazine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00106	0.00327	CcSEcCtD
Sulfadiazine—Convulsion—Vincristine—lymphatic system cancer	0.00106	0.00325	CcSEcCtD
Sulfadiazine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00104	0.00321	CcSEcCtD
Sulfadiazine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00104	0.0032	CcSEcCtD
Sulfadiazine—Vomiting—Fludarabine—lymphatic system cancer	0.00104	0.00319	CcSEcCtD
Sulfadiazine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00103	0.00317	CcSEcCtD
Sulfadiazine—Rash—Fludarabine—lymphatic system cancer	0.00103	0.00316	CcSEcCtD
Sulfadiazine—Dermatitis—Fludarabine—lymphatic system cancer	0.00103	0.00316	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00102	0.00314	CcSEcCtD
Sulfadiazine—Headache—Fludarabine—lymphatic system cancer	0.00102	0.00314	CcSEcCtD
Sulfadiazine—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00102	0.00313	CcSEcCtD
Sulfadiazine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00101	0.00311	CcSEcCtD
Sulfadiazine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000996	0.00306	CcSEcCtD
Sulfadiazine—Anorexia—Carmustine—lymphatic system cancer	0.000995	0.00306	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000975	0.003	CcSEcCtD
Sulfadiazine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00097	0.00298	CcSEcCtD
Sulfadiazine—Nausea—Fludarabine—lymphatic system cancer	0.000968	0.00298	CcSEcCtD
Sulfadiazine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000951	0.00292	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00095	0.00292	CcSEcCtD
Sulfadiazine—Urticaria—Bleomycin—lymphatic system cancer	0.00095	0.00292	CcSEcCtD
Sulfadiazine—Anorexia—Vincristine—lymphatic system cancer	0.00095	0.00292	CcSEcCtD
Sulfadiazine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000945	0.00291	CcSEcCtD
Sulfadiazine—Insomnia—Carmustine—lymphatic system cancer	0.000944	0.0029	CcSEcCtD
Sulfadiazine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000925	0.00284	CcSEcCtD
Sulfadiazine—Ataxia—Methotrexate—lymphatic system cancer	0.000925	0.00284	CcSEcCtD
Sulfadiazine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000908	0.00279	CcSEcCtD
Sulfadiazine—Decreased appetite—Carmustine—lymphatic system cancer	0.000907	0.00279	CcSEcCtD
Sulfadiazine—Insomnia—Vincristine—lymphatic system cancer	0.000901	0.00277	CcSEcCtD
Sulfadiazine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000901	0.00277	CcSEcCtD
Sulfadiazine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000886	0.00272	CcSEcCtD
Sulfadiazine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000884	0.00272	CcSEcCtD
Sulfadiazine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000881	0.00271	CcSEcCtD
Sulfadiazine—Decreased appetite—Vincristine—lymphatic system cancer	0.000866	0.00266	CcSEcCtD
Sulfadiazine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00086	0.00265	CcSEcCtD
Sulfadiazine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000853	0.00262	CcSEcCtD
Sulfadiazine—Pruritus—Bleomycin—lymphatic system cancer	0.000846	0.0026	CcSEcCtD
Sulfadiazine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000843	0.00259	CcSEcCtD
Sulfadiazine—Pancreatitis—Methotrexate—lymphatic system cancer	0.000833	0.00256	CcSEcCtD
Sulfadiazine—Abdominal pain—Carmustine—lymphatic system cancer	0.000825	0.00254	CcSEcCtD
Sulfadiazine—Body temperature increased—Carmustine—lymphatic system cancer	0.000825	0.00254	CcSEcCtD
Sulfadiazine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000815	0.00251	CcSEcCtD
Sulfadiazine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000793	0.00244	CcSEcCtD
Sulfadiazine—Abdominal pain—Vincristine—lymphatic system cancer	0.000787	0.00242	CcSEcCtD
Sulfadiazine—Body temperature increased—Vincristine—lymphatic system cancer	0.000787	0.00242	CcSEcCtD
Sulfadiazine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000771	0.00237	CcSEcCtD
Sulfadiazine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000769	0.00236	CcSEcCtD
Sulfadiazine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000767	0.00236	CcSEcCtD
Sulfadiazine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000767	0.00236	CcSEcCtD
Sulfadiazine—Vomiting—Bleomycin—lymphatic system cancer	0.00076	0.00234	CcSEcCtD
Sulfadiazine—Depression—Methotrexate—lymphatic system cancer	0.000756	0.00232	CcSEcCtD
Sulfadiazine—Rash—Bleomycin—lymphatic system cancer	0.000754	0.00232	CcSEcCtD
Sulfadiazine—Dermatitis—Bleomycin—lymphatic system cancer	0.000753	0.00232	CcSEcCtD
Sulfadiazine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000751	0.00231	CcSEcCtD
Sulfadiazine—Stomatitis—Methotrexate—lymphatic system cancer	0.000739	0.00227	CcSEcCtD
Sulfadiazine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000734	0.00226	CcSEcCtD
Sulfadiazine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000715	0.0022	CcSEcCtD
Sulfadiazine—Diarrhoea—Carmustine—lymphatic system cancer	0.000714	0.0022	CcSEcCtD
Sulfadiazine—Nausea—Bleomycin—lymphatic system cancer	0.00071	0.00218	CcSEcCtD
Sulfadiazine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000707	0.00218	CcSEcCtD
Sulfadiazine—Diarrhoea—Vincristine—lymphatic system cancer	0.000682	0.0021	CcSEcCtD
Sulfadiazine—Hepatitis—Methotrexate—lymphatic system cancer	0.00068	0.00209	CcSEcCtD
Sulfadiazine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000664	0.00204	CcSEcCtD
Sulfadiazine—Vomiting—Carmustine—lymphatic system cancer	0.000663	0.00204	CcSEcCtD
Sulfadiazine—Rash—Carmustine—lymphatic system cancer	0.000658	0.00202	CcSEcCtD
Sulfadiazine—Dermatitis—Carmustine—lymphatic system cancer	0.000657	0.00202	CcSEcCtD
Sulfadiazine—Headache—Carmustine—lymphatic system cancer	0.000654	0.00201	CcSEcCtD
Sulfadiazine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000643	0.00198	CcSEcCtD
Sulfadiazine—Tinnitus—Methotrexate—lymphatic system cancer	0.000634	0.00195	CcSEcCtD
Sulfadiazine—Vomiting—Vincristine—lymphatic system cancer	0.000633	0.00195	CcSEcCtD
Sulfadiazine—Rash—Vincristine—lymphatic system cancer	0.000628	0.00193	CcSEcCtD
Sulfadiazine—Dermatitis—Vincristine—lymphatic system cancer	0.000628	0.00193	CcSEcCtD
Sulfadiazine—Headache—Vincristine—lymphatic system cancer	0.000624	0.00192	CcSEcCtD
Sulfadiazine—Nausea—Carmustine—lymphatic system cancer	0.00062	0.00191	CcSEcCtD
Sulfadiazine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000617	0.0019	CcSEcCtD
Sulfadiazine—Rash—Mitoxantrone—lymphatic system cancer	0.000612	0.00188	CcSEcCtD
Sulfadiazine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000611	0.00188	CcSEcCtD
Sulfadiazine—Chills—Methotrexate—lymphatic system cancer	0.00061	0.00188	CcSEcCtD
Sulfadiazine—Headache—Mitoxantrone—lymphatic system cancer	0.000608	0.00187	CcSEcCtD
Sulfadiazine—Nausea—Vincristine—lymphatic system cancer	0.000592	0.00182	CcSEcCtD
Sulfadiazine—Nausea—Mitoxantrone—lymphatic system cancer	0.000576	0.00177	CcSEcCtD
Sulfadiazine—Vertigo—Methotrexate—lymphatic system cancer	0.000532	0.00164	CcSEcCtD
Sulfadiazine—Leukopenia—Methotrexate—lymphatic system cancer	0.00053	0.00163	CcSEcCtD
Sulfadiazine—Convulsion—Methotrexate—lymphatic system cancer	0.000513	0.00158	CcSEcCtD
Sulfadiazine—Arthralgia—Methotrexate—lymphatic system cancer	0.000504	0.00155	CcSEcCtD
Sulfadiazine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000483	0.00149	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000473	0.00146	CcSEcCtD
Sulfadiazine—Anorexia—Methotrexate—lymphatic system cancer	0.000461	0.00142	CcSEcCtD
Sulfadiazine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00044	0.00135	CcSEcCtD
Sulfadiazine—Insomnia—Methotrexate—lymphatic system cancer	0.000437	0.00134	CcSEcCtD
Sulfadiazine—Decreased appetite—Methotrexate—lymphatic system cancer	0.00042	0.00129	CcSEcCtD
Sulfadiazine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000417	0.00128	CcSEcCtD
Sulfadiazine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000395	0.00122	CcSEcCtD
Sulfadiazine—Urticaria—Methotrexate—lymphatic system cancer	0.000384	0.00118	CcSEcCtD
Sulfadiazine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000382	0.00118	CcSEcCtD
Sulfadiazine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000382	0.00118	CcSEcCtD
Sulfadiazine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000356	0.0011	CcSEcCtD
Sulfadiazine—Pruritus—Methotrexate—lymphatic system cancer	0.000342	0.00105	CcSEcCtD
Sulfadiazine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000331	0.00102	CcSEcCtD
Sulfadiazine—Vomiting—Methotrexate—lymphatic system cancer	0.000307	0.000945	CcSEcCtD
Sulfadiazine—Rash—Methotrexate—lymphatic system cancer	0.000305	0.000937	CcSEcCtD
Sulfadiazine—Dermatitis—Methotrexate—lymphatic system cancer	0.000304	0.000936	CcSEcCtD
Sulfadiazine—Headache—Methotrexate—lymphatic system cancer	0.000303	0.000931	CcSEcCtD
Sulfadiazine—Nausea—Methotrexate—lymphatic system cancer	0.000287	0.000883	CcSEcCtD
